Prospective exploratory evaluation of Cepheid Xpert Mycobacterium tuberculosis host response cartridge: a focus on adolescents and young adults.

IF 8.2 1区 医学 Q1 IMMUNOLOGY Clinical Infectious Diseases Pub Date : 2024-09-05 DOI:10.1093/cid/ciae461
Marva Seifert, Donald G Catanzaro, Michael Gracia, Naomi Hillery, Sabira Tahseen, Faisal Masood, Alamdar Hussain, Uzma Majeed, Rebecca E Coleman, Rehan R Syed, Antonino Catanzaro, Timothy Rodwell
{"title":"Prospective exploratory evaluation of Cepheid Xpert Mycobacterium tuberculosis host response cartridge: a focus on adolescents and young adults.","authors":"Marva Seifert, Donald G Catanzaro, Michael Gracia, Naomi Hillery, Sabira Tahseen, Faisal Masood, Alamdar Hussain, Uzma Majeed, Rebecca E Coleman, Rehan R Syed, Antonino Catanzaro, Timothy Rodwell","doi":"10.1093/cid/ciae461","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>An accurate, rapid, non-sputum-based triage test for diagnosing tuberculosis (TB) is needed.</p><p><strong>Methods: </strong>A prospective evaluation of the Xpert-MTB-HR cartridge, a prototype blood-based host-response mRNA signature assay, among individuals presenting with TB-like symptoms was performed in Pakistan and results were compared to three reference standards: Xpert MTB/RIF Ultra, bacteriological confirmation (Xpert MTB/RIF Ultra and/or culture positivity), and composite clinical diagnosis (clinician diagnosis, treatment initiation, Xpert MTB/RIF Ultra, and/or culture positivity). Analyses were conducted both for the entire study cohort and separately in the adolescent and young adult cohort (ages 10-24).</p><p><strong>Results: </strong>A total of 497 participants, ages 6-83, returned valid Xpert-MTB-HR results. When a diagnostic threshold was set for a sensitivity of >90%, specificity was 32% (95%CI 28-37) when compared to Xpert MTB/RIF Ultra, 29% (95%CI 25-34) when compared to a bacteriological confirmation, and 22% (95%CI 18-26) when compared to a composite clinical diagnosis. However, when evaluating only the adolescent and young adult cohort with a diagnostic threshold set for sensitivity of >90%, specificity was 82% (95%CI 74-89) when compared to Xpert MTB/RIF Ultra, 84% (95%CI 75-90) when compared to a bacteriological confirmation, and 54% (95%CI 44-64) when compared to a composite clinical diagnosis.</p><p><strong>Conclusions: </strong>While the Xpert-MTB-HR does not meet World Health Organization minimum criteria in the general population, in our study it does meet the minimum sensitivity and specificity requirements for a non-sputum-based triage test among adolescents and young adults when compared to Xpert MTB/RIF Ultra or bacteriological confirmation.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":8.2000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae461","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: An accurate, rapid, non-sputum-based triage test for diagnosing tuberculosis (TB) is needed.

Methods: A prospective evaluation of the Xpert-MTB-HR cartridge, a prototype blood-based host-response mRNA signature assay, among individuals presenting with TB-like symptoms was performed in Pakistan and results were compared to three reference standards: Xpert MTB/RIF Ultra, bacteriological confirmation (Xpert MTB/RIF Ultra and/or culture positivity), and composite clinical diagnosis (clinician diagnosis, treatment initiation, Xpert MTB/RIF Ultra, and/or culture positivity). Analyses were conducted both for the entire study cohort and separately in the adolescent and young adult cohort (ages 10-24).

Results: A total of 497 participants, ages 6-83, returned valid Xpert-MTB-HR results. When a diagnostic threshold was set for a sensitivity of >90%, specificity was 32% (95%CI 28-37) when compared to Xpert MTB/RIF Ultra, 29% (95%CI 25-34) when compared to a bacteriological confirmation, and 22% (95%CI 18-26) when compared to a composite clinical diagnosis. However, when evaluating only the adolescent and young adult cohort with a diagnostic threshold set for sensitivity of >90%, specificity was 82% (95%CI 74-89) when compared to Xpert MTB/RIF Ultra, 84% (95%CI 75-90) when compared to a bacteriological confirmation, and 54% (95%CI 44-64) when compared to a composite clinical diagnosis.

Conclusions: While the Xpert-MTB-HR does not meet World Health Organization minimum criteria in the general population, in our study it does meet the minimum sensitivity and specificity requirements for a non-sputum-based triage test among adolescents and young adults when compared to Xpert MTB/RIF Ultra or bacteriological confirmation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cepheid Xpert 结核分枝杆菌宿主反应盒的前瞻性探索评估:聚焦青少年。
背景:需要一种准确、快速、无痰的肺结核分诊试验:需要一种准确、快速、无痰的结核病诊断分诊试验:方法:在巴基斯坦对 Xpert-MTB-HR 血盒(一种基于血液的宿主反应 mRNA 特征检测原型)进行了前瞻性评估,并将评估结果与三种参考标准进行了比较:结果与三个参考标准进行了比较:Xpert MTB/RIF Ultra、细菌学确证(Xpert MTB/RIF Ultra 和/或培养阳性)和综合临床诊断(临床医生诊断、开始治疗、Xpert MTB/RIF Ultra 和/或培养阳性)。对整个研究队列以及青少年和年轻成人队列(10-24 岁)分别进行了分析:结果:共有 497 名 6-83 岁的参与者返回了有效的 Xpert-MTB-HR 结果。当诊断阈值设定为灵敏度大于 90% 时,与 Xpert MTB/RIF Ultra 相比,特异性为 32% (95%CI 28-37);与细菌学确诊相比,特异性为 29% (95%CI 25-34);与综合临床诊断相比,特异性为 22% (95%CI 18-26)。然而,如果只评估青少年和年轻成人组群,并将诊断阈值设定为灵敏度大于 90%,那么与 Xpert MTB/RIF Ultra 相比,特异性为 82%(95%CI 74-89),与细菌学确诊相比,特异性为 84%(95%CI 75-90),与综合临床诊断相比,特异性为 54%(95%CI 44-64):虽然在普通人群中,Xpert-MTB-HR 并不符合世界卫生组织的最低标准,但在我们的研究中,与 Xpert MTB/RIF Ultra 或细菌学确诊相比,它确实符合青少年和年轻成人非痰检分流测试的最低灵敏度和特异性要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
期刊最新文献
OPAT and Severe Sepsis Mortality. Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation. Gauging Medical Students' Interests in Infectious Diseases. Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023. Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1